SCYNEXIS, Inc. (SCYX) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $5.45, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $36.55 vs price $5.18 — ratio 7.1×). Rejected, falling back to technical TP.; Market cap $52M below $400M minimum.
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and... Read more
Hold if already holding. Not a fresh buy at $5.45, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $36.55 vs price $5.18 — ratio 7.1×). Rejected, falling back to technical TP.; Market cap $52M below $400M minimum. Chart setup: Death cross but MACD improving, RSI 77. Market cap $52M below $400M minimum. Not in investable universe. Score 5.4/10, moderate confidence.
Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
Recent developments
updated 2026-08-17Recent Developments — SCYNEXIS, Inc.
Latest news
- NEWS Guggenheim Maintains Buy on SCYNEXIS, Raises Price Target to $33 — benzinga Aug 13, 2026
- NEWS UPDATE: SCYNEXIS Q2 Adj. EPS $(0.57) Misses $(0.51) Estimate, Sales $235.000K Beat $80.330K Estimate — benzinga Aug 10, 2026
- NEWS SCYNEXIS Q2 EPS $0.63 Beats $(0.64) Estimate, Sales $235.000K Beat $80.330K Estimate — benzinga Aug 10, 2026
Generated 2026-08-17T13:27:14Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -53.3%. Quality floor flags this regardless of sector context.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $5.45, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $36.55 vs price $5.18 — ratio 7.1×). Rejected, falling back to technical TP.; Market cap $52M below $400M minimum. Chart setup: Death cross but MACD improving, RSI 77. Market cap $52M below $400M minimum. Not in investable universe. Target $5.43 (-0.4%), stop $4.82 (−13.1%), A.R:R 0.0:1. Score 5.4/10, moderate confidence.
Take-profit target: $5.43 (+4.8% upside). Target $5.43 (-0.4%), stop $4.82 (−13.1%), A.R:R 0.0:1. Stop-loss: $4.82.
DATA_ISSUE: analyst_target_implausible (raw $36.55 vs price $5.18 — ratio 7.1×). Rejected, falling back to technical TP.; Market cap $52M below $400M minimum.
SCYNEXIS, Inc. trades at a P/E of N/A (forward -2.2). TrendMatrix value score: 8.5/10. Verdict: Hold.
9 analysts cover SCYX with a consensus score of 4.2/5. Average price target: $37.
What does SCYNEXIS, Inc. do?SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of...
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.